Atezolizumab in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have not received prior systemic therapy.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||21/12/2020|
|Rapid review completed||08/02/2021|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of atezolizumab in combination with bevacizumab compared with the current standard of care.|